ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
2.060
-0.020 (-0.96%)
At close: Jan 23, 2026, 4:00 PM EST
2.090
+0.030 (1.46%)
After-hours: Jan 23, 2026, 7:55 PM EST
ABVC BioPharma Employees
As of December 31, 2024, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$41,996
Profits / Employee
-$267,220
Market Cap
48.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 19 | 0 | - | 16 | 3 |
| Dec 31, 2023 | 19 | -4 | -17.39% | 16 | 3 |
| Dec 31, 2022 | 23 | -7 | -23.33% | 19 | 4 |
| Dec 31, 2021 | 30 | -4 | -11.76% | 28 | 2 |
| Dec 31, 2020 | 34 | -4 | -10.53% | 30 | 4 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Q32 Bio | 26 |
| Plus Therapeutics | 21 |
| NeurAxis | 21 |
| iBio, Inc. | 20 |
| Instil Bio | 14 |
| OS Therapies | 5 |
| Lite Strategy | 4 |
ABVC News
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 1 year ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 1 year ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 1 year ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 1 year ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 2 years ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire